Status:
COMPLETED
Buprenorphine and Integrated HIV Care
Lead Sponsor:
Yale University
Collaborating Sponsors:
The New York Academy of Medicine
Conditions:
Substance-related Disorders
Drug Addiction
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine the efficacy of providing two levels of psychosocial support along with buprenorphine/naloxone (BUP) maintenance to opioid dependent patients receiving their ca...
Detailed Description
The purpose of this study is to examine the efficacy of providing two levels of psychosocial support along with buprenorphine/naloxone (BUP) maintenance to opioid dependent patients receiving their ca...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- HIV disease
- DSM-IV criteria for opioid dependence, as assessed by SCID
- Documented opioid positive urine toxicology testing
- Exclusion criteria:
- Desire to remain enrolled in opioid agonist treatment at an opioid treatment program
- Current dependence on alcohol, benzodiazepines or sedatives (patients who are receiving benzodiazepines under the care of a psychiatrist for the treatment of an anxiety disorder will not be excluded)
- Current suicide or homicide risk
- Current psychotic disorder or major depression
- Inability to read or understand English
- Dementia
- Life-threatening or unstable medical problems requiring inpatient medical care or nursing home placement
- Currently enrolled in other studies involving the provision of psychosocial treatment.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00317460
Start Date
September 1 2005
End Date
October 1 2012
Last Update
April 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University School of Medicine
New Haven, Connecticut, United States, 06519